Cadonilimab

卡度尼利单抗

Report date: 2026/05/06 20:02:28
First In Class

Base Information

Drug NameCadonilimab
Drug Alias Name凯得宁单抗CaldonirimabCandonilimab卡多尼单抗cardonilizumab +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMicrosatellite instability-high cancer +[29] 
Global Approved IndicationsUterine Cervical Neoplasms
Approved Indications in ChinaUterine Cervical Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2022/06/29
Country/TerritoryUnited StatesNew ZealandAustralia +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhongshan Akeso Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncKangfang Biotechnology (Cayman) Co LtdAkeso-Sino Pharma Co Ltd +[12] 
Inactive CompaniesGuangxi Medical University
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMicrosatellite instability-high cancer +[27] 
Inactive IndicationsSmall Cell Lung CarcinomaNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG